Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With Unresectable Intermediate‐Stage Hepatocellular Carcinoma: A Multicenter Cohort Study.
Saved in:
| Title: | Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With Unresectable Intermediate‐Stage Hepatocellular Carcinoma: A Multicenter Cohort Study. |
|---|---|
| Authors: | Taniki, Nobuhito1 (AUTHOR) nobuhitotaniki@keio.jp, Ojiro, Keisuke1,2 (AUTHOR), Kasuga, Ryosuke1 (AUTHOR), Nakadai, Yukie1 (AUTHOR), Tabuchi, Takaya1 (AUTHOR), Chu, Po‐Sung1 (AUTHOR), Usui, Shingo1 (AUTHOR), Hoshi, Hitomi3 (AUTHOR), Kaneko, Fumihiko3 (AUTHOR), Yamaguchi, Akihiro4 (AUTHOR), Koizumi, Jun5 (AUTHOR), Ebinuma, Hirotoshi1,6 (AUTHOR), Tamura, Masashi7 (AUTHOR), Tsukada, Jitsuro7 (AUTHOR), Inoue, Masanori7,8 (AUTHOR), Nakatsuka, Seishi7 (AUTHOR), Hasegawa, Yasushi9 (AUTHOR), Abe, Yuta9 (AUTHOR), Kitago, Minoru9 (AUTHOR), Jinzaki, Masahiro7 (AUTHOR) |
| Source: | Cancer Medicine. Jan2026, Vol. 15 Issue 1, p1-9. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
